NOVO-B

Novo Nordisk entered 2026 as the most consequential healthcare company in Europe, and quite possibly the most structurally important pharmaceutical franchise of the decade. Its market capitalization of approximately DKK 1.06 trillion (roughly EUR 142 billion at current exchange rates) makes it the single largest company in the STOXX 600 by healthcare weighting. Yet the share price at DKK 238 sits 55% below its 52-week high of DKK 533, a collapse in valuation that would normally signal a company in crisis. Novo Nordisk is not in crisis. It is in something more analytically interesting: the transition from hypergrowth to structural dominance, a phase where the market must decide whether it is pricing a growth stock or a franchise.

The central question for this analysis is not whether Novo Nordisk has a moat. It does. The question is whether the moat justifies the industrial transformation the company is now undertaking, and whether the competitive environment that was once entirely on its terms is beginning to shift. Between 2021 and 2025, Novo Nordisk's revenue more than doubled from DKK 140.8 billion to DKK 309.1 billion. Net income moved from DKK 47.8 billion to DKK 102.4 billion. These are not incremental gains. This is the financial signature of a company that created, then captured, one of the largest new therapeutic categories in pharmaceutical history: GLP-1 receptor agonists for diabetes and obesity.

The L17X insight on Novo Nordisk is this: the company's greatest strategic risk is not competition from Eli Lilly, nor regulatory pressure on drug pricing, nor even the inevitable plateau of the obesity curve. It is that Novo Nordisk has committed to a manufacturing infrastructure buildout of historic proportions (DKK 90 billion in capital expenditure in FY2025 alone) at precisely the moment when the market is beginning to question whether GLP-1 demand will remain supply-constrained or shift to price-constrained. If the bottleneck moves from factories to formularies, the entire investment thesis changes. This is a company betting its balance sheet on the thesis that the world will need more semaglutide than it can currently produce. That bet may be correct, but the magnitude of the capital commitment means the consequences of being wrong are severe. Novo Nordisk is not simply defending a market position. It is building an industrial fortress around a molecular franchise, and the question is whether the walls are going up fast enough, or whether they are going up around the wrong perimeter.